BCTX

Briacell Therapeutics Corp

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

Briacell Therapeutics Corp Stock Price

Vitals

Today's Low:
$5.2700
Today's High:
$5.6300
Open Price:
$5.2700
52W Low:
$4.06
52W High:
$12.47
Prev. Close:
$5.3300
Volume:
171135

Company Statistics

Market Cap.:
$0.083 billion
Book Value:
0.666
Revenue TTM:
$0.000 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-19%
Return on Equity TTM:
-141.3%

Company Profile

Briacell Therapeutics Corp had its IPO on 2021-02-24 under the ticker symbol BCTX.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Briacell Therapeutics Corp has a staff strength of 0 employees.

Stock update

Shares of Briacell Therapeutics Corp opened at $5.27 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $5.27 - $5.63, and closed at $5.35.

This is a +0.38% increase from the previous day's closing price.

A total volume of 171,135 shares were traded at the close of the day’s session.

In the last one week, shares of Briacell Therapeutics Corp have increased by +7%.

Briacell Therapeutics Corp's Key Ratios

Briacell Therapeutics Corp has a market cap of $0.083 billion, indicating a price to book ratio of 8.26 and a price to sales ratio of -.

In the last 12-months Briacell Therapeutics Corp’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.015 billion. The EBITDA ratio measures Briacell Therapeutics Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Briacell Therapeutics Corp’s operating margin was 0% while its return on assets stood at -19% with a return of equity of -141.3%.

In Q2.3333333333333, Briacell Therapeutics Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Briacell Therapeutics Corp’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-0.946 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Briacell Therapeutics Corp’s profitability.

Briacell Therapeutics Corp stock is trading at a EV to sales ratio of - and a EV to EBITDA ratio of -1.087. Its price to sales ratio in the trailing 12-months stood at -.

Briacell Therapeutics Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Briacell Therapeutics Corp ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Briacell Therapeutics Corp ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Briacell Therapeutics Corp’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Briacell Therapeutics Corp's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Briacell Therapeutics Corp paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$5.35
52-Week High
$12.47
52-Week Low
$4.06
Analyst Target Price
$20

Briacell Therapeutics Corp stock is currently trading at $5.35 per share. It touched a 52-week high of $12.47 and a 52-week low of $12.47. Analysts tracking the stock have a 12-month average target price of $20.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Briacell Therapeutics Corp

The stock symbol (also called stock or share ticker) of Briacell Therapeutics Corp is BCTX

The IPO of Briacell Therapeutics Corp took place on 2021-02-24

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$3.28
-0.07
-2.09%
$14.81
-0.62
-4.02%
$0.7
-0.03
-4.38%
$15.18
-0.82
-5.13%
$10.28
-0.46
-4.28%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

BriaCell Therapeutics Corp. The company is headquartered in West Vancouver, Canada.

Address

3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER, BC, CA